腹主动脉瘤患者血浆DDP4水平与动脉瘤进展的关系

毕远航; 王吉昌; 付浩哲

doi:10.11659/jjssx.01E024145

您当前的位置：

首页 >

文章列表页 >

腹主动脉瘤患者血浆DDP4水平与动脉瘤进展的关系

临床研究 | 更新时间：2025-01-16

- 腹主动脉瘤患者血浆DDP4水平与动脉瘤进展的关系
- Relationship between plasma DDP4 level and aneurysm progression in patients with abdominal aortic aneurysm
- 局解手术学杂志 2025年34卷第1期页码：67-71
- 作者机构：
  
  1.宝鸡市中心医院血管外科，陕西宝鸡 721000
  2.西安交通大学第一附属医院血管外科，陕西西安 710000
- 作者简介：
  
  付浩哲，E-mail：fhzwywfyy@163.com
- 基金信息：
  
  陕西省科学技术研究发展计划项目(2020J16-06-01)
- DOI：10.11659/jjssx.01E024145
  中图分类号： R654.3
- 纸质出版日期：2025-01-25，
  
  收稿日期：2024-01-30，
- 稿件说明：
移动端阅览
毕远航, 王吉昌, 付浩哲. 腹主动脉瘤患者血浆DDP4水平与动脉瘤进展的关系[J]. 局解手术学杂志, 2025,34(1):67-71.

BI YUAN-HANG, WANG JI-CHANG, FU HAO-ZHE. Relationship between plasma DDP4 level and aneurysm progression in patients with abdominal aortic aneurysm. [J]. Journal of regional anatomy and operative surgery, 2025, 34(1): 67-71.
毕远航, 王吉昌, 付浩哲. 腹主动脉瘤患者血浆DDP4水平与动脉瘤进展的关系[J]. 局解手术学杂志, 2025,34(1):67-71. DOI： 10.11659/jjssx.01E024145.

BI YUAN-HANG, WANG JI-CHANG, FU HAO-ZHE. Relationship between plasma DDP4 level and aneurysm progression in patients with abdominal aortic aneurysm. [J]. Journal of regional anatomy and operative surgery, 2025, 34(1): 67-71. DOI： 10.11659/jjssx.01E024145.

摘要

目的

探讨腹主动脉瘤患者血浆二肽基肽酶4（DDP4）水平与动脉瘤进展的关系。

方法

选取2020年1月至2021年5月宝鸡市中心医院收治的43例腹主动脉瘤患者为研究对象。随访至少12个月，根据首次和末次计算机断层扫描血管造影数据获取最大瘤体前后直径的绝对测量值和进展速度，根据腹主动脉瘤进展速度将患者分为进展组（进展速度≥0.5 mm/年）和无进展组（进展速度

0.5 mm/年），比较2组患者临床特征。酶联免疫吸附法检测患者入院时血浆DDP4水平。采用

Pearson

相关性和多元线性回归分析DDP4与腹主动脉瘤进展速度的相关性。使用

Logistic

回归模型和受试者工作特征（

ROC

）曲线分析血浆DDP4对腹主动脉瘤进展的预测效能。

结果

进展组患者腔内血栓厚度（

=0.046）和腹主动脉瘤进展速度（

0.001）大/快于无进展组，且血浆DDP4水平显著高于无进展组（

0.001）。多因素

Logistic

回归分析显示，血浆DDP4水平是腹主动脉瘤进展的独立预测因素（

0.05）。经

Pearson

相关性分析，血浆DDP4水平与腹主动脉瘤进展速度呈显著正相关（

=0.517，

0.001）。经多元线性回归校正其他混杂因素后，血浆DDP4水平与腹主动脉瘤进展速度仍呈显著正相关（

=0.312，95%

：0.002~0.484，

=0.048）。基线血浆DDP4水平预测腹主动脉瘤进展的曲线下面积为0.840（95%

：0.704~0.976），对应截断值为13.89 pg/mL，特异度为85.7%，敏感度为79.3%。

结论

腹主动脉瘤患者血浆DDP4水平升高与腹主动脉瘤进展高风险有关，血浆DDP4有望成为预测腹主动脉瘤进展的生物标志物。

Abstract

Objective

To investigate the relationship between plasma dipeptidyl peptidase 4 （DDP4） level and the progression of abdominal aortic aneurysm.

Methods

Forty-three

patients with abdominal aortic aneurysm admitted to Baoji Central Hospital from January 2020 to May 2021 were selected. The follow-up was conducted at least 12 months， the absolute measurement of the maximum anterior-posterior diameters of the aneurysm and the rate of progression were obtained based on the first and last computed tomography angiography data， and the patients were divided into the progression group （with the rate of progression≥0.5 mm/year） and the progression-free group （with the rate of progression

0.5 mm/year） according to the rate of the abdominal aortic aneurysm progression. The clinical characteristics of the two groups were compared. Plasma DDP4 levels were detected by enzyme-linked immunosorbent assay. The correlation between plasma DDP4 and the rate of abdominal aortic aneurysm progression was analyzed by

Pearson

correlation and multiple linear regression. The predictive performance of plasma DDP4 on abdominal aortic aneurysm progression was analyzed by

Logistic

regression model and

receiver operating characteristic

（

ROC

） curve.

Results

The thickness of intracavitary thrombus （

=0.046） and the rate of abdominal aortic aneurysm progression （

0.001） in the progression group were greater/faster than those in the the progression-free group， and the plasma level of DDP was significantly higher than that in the progression-free group （

0.001）. Multivariate

Logistic

regression analysis showed that plasma DDP4 level was an independent predictor of abdominal aortic aneurysm progression （

0.05）.

Pearson

correlation analysis showed that plasma DDP4 level was positively correlated with the rate of abdominal aortic aneurysm progression （

=0.517，

0.001）. After adjusting for other confounding factors， multiple linear regression showed that there was s

till a significantly positive correlation between plasma DDP4 level and abdominal aortic aneurysm progression rate （

=0.312， 95%

：0.002 to 0.484，

=0.048）.The area under the curve of baseline plasma DDP4 level for predicting abdominal aortic aneurysm progression was 0.840 （95%

：0.704 to 0.976）， with corresponding cutoff value of 13.89 pg/mL， specificity of 85.7%， and sensitivity of 79.3%.

Conclusion

Elevated plasma DDP4 levels in patients with abdominal aortic aneurysm are associated with a higher risk of aneurysm progression. Plasma DDP4 is expected to be a predictive biomarker for abdominal aortic aneurysm progression.

关键词

腹主动脉瘤血浆二肽基肽酶4疾病进展

Keywords

abdominal aortic aneurysmplasma dipeptidyl peptidase 4disease progression

references

Song P，He Y，Adeloye D，et al.The global and regional prevalence of abdominal aortic aneurysms：a systematic review and modeling analysis［J］.Ann Surg，2023，277（6）：912-919.doi：10.1097/SLA.0000000000005716http://dx.doi.org/10.1097/SLA.0000000000005716.

Kessler V，Klopf J，Eilenberg W，et al.AAA revisited：a comprehensive review of risk factors，management，and hallmarks of pathogenesis［J］.Biomedicines，2022，10（1）：94-127.doi：10.3390/biomedicines10010094http://dx.doi.org/10.3390/biomedicines10010094.

Golledge J，Thanigaimani S，Powell JT，et al.Pathogenesis and management of abdominal aortic aneurysm［J］.Eur Heart J，2023，44（29）：2682-2697.doi：10.1093/eurheartj/ehad386http://dx.doi.org/10.1093/eurheartj/ehad386.

王蓓明，冯增利，刘艳，等.转胶蛋白调控腹主动脉瘤形成机制的实验研究［J］.局解手术学杂志，2023，32（11）：968-974.doi：10.11659/jjssx.09E022149http://dx.doi.org/10.11659/jjssx.09E022149.

Nana P，Dakis K，Brodis A，et al.Circulating biomarkers for the prediction of abdominal aortic aneurysm growth［J］.J Clin Med，2021，10（8）：1718-1735.doi：10.3390/jcm10081718http://dx.doi.org/10.3390/jcm10081718.

陈静，张尚暖.铁死亡相关基因DPP4与肿瘤免疫及预后的生物信息学研究［J］.中国免疫学杂志，2023，39（11）：2348-2354.doi：10.3969/j.issn.1000-484X.2023.11.018http://dx.doi.org/10.3969/j.issn.1000-484X.2023.11.018.

Love KM，Liu Z.DPP4 activity，hyperinsulinemia，and atherosclerosis［J］.J Clin Endocrinol Metab，2021，106（6）：1553-1565.doi：10.1210/clinem/dgab078http://dx.doi.org/10.1210/clinem/dgab078.

Piao L，Li Y，Narisawa M，et al.Role of dipeptidyl peptidase-4 in atherosclerotic cardiovascular disease in humans and animals with chronic tress［J］.Int Heart J，2021，62（3）：470-478.doi：10.1536/ihj. 20-181http://dx.doi.org/10.1536/ihj.20-181.

陈保林，姜焱，伍红瑜，等.甲状腺乳头状癌中DDP4的表达及临床意义［J］.临床与实验病理学杂志，2021，37（9）：1122-1124.doi：10.13315/j.cnki.cjcep.2021.09.023http://dx.doi.org/10.13315/j.cnki.cjcep.2021.09.023.

钟玉梅，钟雪玉，周卫平，等.2型糖尿病颈动脉粥样硬化患者血清二肽基肽酶4和氧化低密度脂蛋白水平改变［J］.中国糖尿病杂志，2022，30（2）：111-115.doi：10.3969/j.issn.1006-6187.2022.02.007http://dx.doi.org/10.3969/j.issn.1006-6187.2022.02.007.

Lindquist Liljeqvist M，Eriksson L，Villard C，et al.Dipeptidyl peptidase-4 is increased in the abdominal aortic aneurysm vessel wall and is associated with aneurysm disease processes［J］.PLoS One，2020，15（1）：e0227889.doi：10.1371/journal.pone.0227889http://dx.doi.org/10.1371/journal.pone.0227889.

Ngetich E，Lapolla P，Chandrashekar A，et al.The role of dipeptidyl peptidase-Ⅳ in abdominal aortic aneurysm pathogenesis：a systematic review［J］.Vasc Med，2022，27（1）：77-87.doi：10.1177/1358863X211034574http://dx.doi.org/10.1177/1358863X211034574.

Takahara Y， Tokunou T， Ichiki T.Suppression of abdominal aortic aneurysm formation in mice by teneligliptin， a dipeptidyl peptidase-4 inhibitor［J］.J Atheroscler Thromb，2018，25（8）：698-708. doi： 10.5551/jat.42481http://dx.doi.org/10.5551/jat.42481.

Ahmad M，Kuravi S，Hodson J，et al.The relationship between serum interleukin-1α and asymptomatic infrarenal abdominal aortic aneurysm size， morphology， and growth rates［J］.Eur J Vasc Endovasc Surg， 2018，56（1）：130-135. doi： 10.1016/j.ejvs.2018.01.015http://dx.doi.org/10.1016/j.ejvs.2018.01.015.

Qian G，Adeyanju O，Olajuyin A，et al.Abdominal aortic aneurysm formation with a focus on vascular smooth muscle cells［J］.Life，2022，12（2）：191-206.doi：10.3390/life12020191http://dx.doi.org/10.3390/life12020191.

Lu H，Du W，Ren L，et al.Vascular smooth muscle cells in aortic aneurysm：from genetics to mechanisms［J］.J Am Heart Assoc，2021，10（24）：e023601.doi：10.1161/JAHA.121.023601http://dx.doi.org/10.1161/JAHA.121.023601.

Chen J， Hu L， Liu Z. Medical treatments for abdominal aortic aneurysm： an overview of clinical trials［J］. Expert Opin Investig Drugs，2024，33（9）：979-992.doi：10.1080/13543784.2024.2377747http://dx.doi.org/10.1080/13543784.2024.2377747.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

转胶蛋白调控腹主动脉瘤形成机制的实验研究